NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

非酒精性脂肪性肝炎(NASH):到2029年的流行病學預測

Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029

出版商 GlobalData 商品編碼 944086
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
非酒精性脂肪性肝炎(NASH):到2029年的流行病學預測 Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029
出版日期: 2020年06月15日內容資訊: 英文 35 Pages
簡介

世界上七個主要國家(美國,日本,英國,德國,法國,西班牙,意大利)的非酒精性脂肪性肝炎(NASH)確診病例在2019年為26124484例,到2029年為3413例。未來十年,預計將增加到9,592例,增長率為3.07%。 GlobalData研究預測,開發侵入性較小的診斷方法,提高醫生的意識以及實施篩查程序可能會導致更高的總病例數和診斷患病率..此外,遺傳研究表明PNPLA3多態性與NAFLD或NASH密切相關,這是未來的研究領域。

該報告調查了全世界的非酒精性脂肪性肝炎(NASH),並提供了諸如疾病概述,未來趨勢預測和醫療保健業務戰略等信息。

內容

第1章內容

  • 表列表
  • 圖形列表

第2章調查摘要

第3章流行病學

  • 疾病背景
  • 風險因素和合併症
  • 世界和過去的趨勢
    • NASH的總患病率
    • 經診斷的NASH患病率
  • 預測調查方法
    • 信息
    • 未使用的信息
    • 預測假設和方法
    • NASH病例總數
    • NASH診斷病例
    • 在纖維化各個階段被診斷出的NASH病例
  • NASH流行病學預測(2019-2029)
    • 案件總數
    • 診斷病例
    • 按年齡
    • 性別
    • 纖維化階段對NASH的診斷
  • 討論
    • 流行病學預測見解
    • 分析限制
    • 分析實力

第4章附錄

  • 參考
  • 主要調查:處方者調查
  • 關於作者
    • 流行病學家
    • 審稿人
    • 治療分析和流行病學世界總監
    • 醫療保健業務/策略:世界領導者兼執行副總裁
  • 關於全球數據
  • 聯繫我們
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER244-20

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016).

GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cases were segmented by age and sex, and were then further segmented by NASH stage of fibrosis. Since obesity is a major risk factor for NASH, the historical, country-specific prevalence trends in obesity were incorporated to determine the prevalence trends in NASH.

GlobalData epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by an annual growth rate (AGR) of 0.55% over the next 10 years, from 68,302,915 cases in 2019 to 72,059,723 cases in 2029. For diagnosed prevalent cases, GlobalData epidemiologists forecast that the 7MM will grow by an AGR of 3.07% over the next 10 years, from 26,124,484 cases in 2019 to 34,139,592 cases in 2029. For the stage of fibrosis in 2019, stages F0-F1 were the most common stages, representing 30.47% of diagnosed prevalent cases of NASH. GlobalData epidemiologists expect that the development of less-invasive diagnostic methods, increased physician awareness, and screening programs may drive the number of total and diagnosed prevalent cases higher. Additionally, genetic research has shown that PNPLA3 polymorphisms have a strong association with NAFLD, and therefore NASH, making it a future area of study.

Scope

  • The Non-Alcoholic Steatohepatitis Epidemiology Report provides an overview of the risk factors, comorbidities, and global trends of Non-Alcoholic Steatohepatitis (NASH) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age (0-17 years, 18-29, and by 10-year age groups up to 80 years and older) and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by stage of fibrosis (F0-F1, F2, F3, and F4). In addition, the epidemiology model corresponding to this report provides the total and diagnosed prevalent cases of NAFLD in ages 18 years and older.
  • The NASH epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

  • The NASH Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global NASH markets.
  • Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
  • Understand magnitude of NASH population by stage of fibrosis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Non-Alcoholic Steatohepatitis: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
    • 3.3.1 Total Prevalence of NASH (%)
    • 3.3.2 Diagnosed Prevalence of NASH (%)
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
    • 3.4.4 Total Prevalent Cases of NASH
    • 3.4.5 Diagnosed Prevalent Cases of NASH
    • 3.4.6 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • 3.5 Epidemiological Forecast for NASH (2019-2029)
    • 3.5.1 Total Prevalent Cases of NASH
    • 3.5.2 Diagnosed Prevalent Cases of NASH
    • 3.5.3 Age-Specific Diagnosed Prevalent Cases of NASH
    • 3.5.4 Sex-Specific Diagnosed Prevalent Cases of NASH
    • 3.5.5 Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Risk Factors and Comorbidities for NASH
  • Table 3: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
  • Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of NASH, Both Sexes, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, 2019 and 2029
  • Figure 3: 7MM, Total Prevalence of NASH (%), Both Sexes, All Ages, 2009*2029
  • Figure 4: 7MM, Diagnosed Prevalence of NASH (%), Both Sexes, All Ages, 2009*2029
  • Figure 5: 7MM, Sources Used for NASH Total Prevalence
  • Figure 6: 7MM, Sources Used for Obesity Prevalence
  • Figure 7: 7MM, Sources Used for the Diagnosed Prevalent Cases of NASH and Diagnosed Prevalent Cases of NASH by Stage of Fibrosis
  • Figure 8: 7MM, Total Prevalent Cases of NASH, Both Sexes, All Ages, 2019
  • Figure 9: 7MM, Diagnosed Prevalent Cases of NASH, Both Sexes, All Ages, 2019
  • Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of NASH, Both Sexes, 2019
  • Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of NASH, All Ages, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of NASH by Stage of Fibrosis, Both Sexes, All Ages, 2019